Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.34 |
| ▸ | GABRD | O14764 | 2/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | GABRE | P78334 | 2/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.34 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28096046 | 1.00 | LMNA (0.46) | LMNASLC1A1TSHRMAPTGABRP | |
| SCHEMBL2241803 | 1.00 | LMNA (0.46) | LMNASLC1A1TSHRMAPTGABRP | |
| SCHEMBL22639581 | 0.89 | SLC1A1 (0.49) | LMNASLC1A1TSHRMAPTGABRP | |
| SCHEMBL16523558 | 0.89 | LMNA (0.43) | LMNASLC1A1TSHRMAPTGABRP | |
| SCHEMBL16523559 | 0.87 | LMNA (0.46) | LMNASLC1A1TSHRGABRPGABRD | |
| SCHEMBL31229067 | 0.87 | CYP1A2 (0.44) | LMNASLC1A1GABRPGABRDGABRA1 | |
| SCHEMBL14175423 | 0.87 | CYP1A2 (0.44) | LMNASLC1A1GABRPGABRDGABRA1 | |
| SCHEMBL2201201 | 0.84 | SLC1A1 (0.54) | LMNASLC1A1GRM8GRM6GRIN2D | |
| SCHEMBL23515280 | 0.84 | SLC1A1 (0.36) | LMNASLC1A1GABRPGABRDGABRA1 | |
| SCHEMBL5885314 | 0.84 | SLC1A1 (0.36) | LMNASLC1A1GABRPGABRDGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102796097-B | Phenanthroindolizididerivative pyridine alcaloid-derivatives, its preparation method and pharmaceutical composition and purposes | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-12-14 | — | — | CN | claimed |
| EP-1603549-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| WO-2004082628-A2 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-30 | — | — | WO | claimed |
| JP-9143497-A | — | — | None | — | — | JP | disclosed |
| CN-108794372-B | Novel compound and pharmaceutical composition for treating tuberculosis comprising same | 顺天乡大学校产学协力团 | 2021-09-14 | — | — | CN | disclosed |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-09-26 | — | — | US | disclosed |
| CN-105924380-B | Luxuriant and rich with fragrance class compound or derivatives thereof and treatment medicine for tuberculosis compositions containing the phenanthrene class compound or derivatives thereof | 顺天乡大学校产学协力团 | 2019-03-05 | — | — | CN | disclosed |
| CN-108794372-A | New compound and tuberculotherapy medical composition comprising it | 顺天乡大学校产学协力团 | 2018-11-13 | — | — | CN | disclosed |
| CN-102796097-B | Phenanthroindolizididerivative pyridine alcaloid-derivatives, its preparation method and pharmaceutical composition and purposes | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2016-12-14 | — | — | CN | disclosed |
| CN-101365415-B | Gelling agent | AJINOMOTO KK | 2012-09-12 | — | — | CN | disclosed |
| US-8084499-B2 | Modified clay mineral | AJINOMOTO CO., INC. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-4866093-A | INHIBITING CHOLESTEROL BIOSYNTHESIS IN THE LIVER | SANKYO COMPANY LIMITED (JP) | 1989-09-12 | — | — | US | disclosed |
| US-4695587-A | CHOLESTEROL BIOSYNTHESIS INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1987-09-22 | — | — | US | disclosed |
| EP-0065835-B1 | M-4 AND ISO M-4 DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1985-11-13 | — | — | EP | disclosed |
| EP-0065843-B1 | NEW M-4 AND ISO M-4 DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SANKYO COMPANY LIMITED (JP) | 1985-09-18 | — | — | EP | disclosed |
| US-4479965-A | ANTILIPEMIC, ANTICHOLESTEROL AGENTS | SANKYO COMPANY, LIMITED (JP) | 1984-10-30 | — | — | US | disclosed |
| US-4451481-A | ANTICHOLESTEROL AGENTS | SANKYO COMPANY LIMITED (JP) | 1984-05-29 | — | — | US | disclosed |
| EP-0065835-A1 | M-4 and iso M-4 derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1982-12-01 | — | — | EP | disclosed |
| EP-0065843-A1 | New M-4 and iso M-4 derivatives, their preparation and compositions containing them | SANKYO COMPANY LIMITED (JP) | 1982-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | LMNA 1933/4885SLC1A1 3154/4885TSHR 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.